Schwarz Herbert
National University of Singapore, 2 Medical Drive, MD 9, Singapore 117597.
J Leukoc Biol. 2005 Mar;77(3):281-6. doi: 10.1189/jlb.0904558. Epub 2004 Dec 23.
CD137 is a member of the tumor necrosis factor receptor family and a potent regulator of T cell activities. Agonists of CD137 have been used widely and successfully to treat cancer in animal models, and recently, it has become evident that CD137 agonists can also be used to treat autoimmune disease. An aspect of the CD137 receptor/ligand system, which has been comparatively little-explored, is its ability of reverse signaling. Just as is CD137, the CD137 ligand is also expressed as a cell membrane protein, and it too can transduce signals into the cells on which it is expressed. This bidirectional signaling capacity allows the CD137 receptor/ligand system to mediate extensive cross-talk between immune cells and between immune and nonimmune cells. This review summarizes the known activities of the CD137 ligand on the different leukocyte subsets and on cancer cells and discusses their influence on the course of immune responses.
CD137是肿瘤坏死因子受体家族的成员,也是T细胞活性的有效调节剂。CD137激动剂已被广泛且成功地用于动物模型中的癌症治疗,最近,越来越明显的是,CD137激动剂也可用于治疗自身免疫性疾病。CD137受体/配体系统中一个相对较少被探索的方面是其反向信号传导能力。与CD137一样,CD137配体也作为细胞膜蛋白表达,并且它也可以将信号转导到其表达的细胞中。这种双向信号传导能力使CD137受体/配体系统能够介导免疫细胞之间以及免疫细胞与非免疫细胞之间广泛的相互作用。本综述总结了CD137配体在不同白细胞亚群和癌细胞上的已知活性,并讨论了它们对免疫反应过程的影响。